- Article
Does the Efficacy of Semaglutide Treatment Differ between Low-Risk and High-Risk Subgroups of Patients with Type 2 Diabetes and Obesity Based on SCORE2, SCORE2-Diabetes, and ASCVD Calculations?
- Martina Matovinović,
- Andrej Belančić,
- Juraj Jug,
- Filip Mustač,
- Maja Sirovica,
- Mihovil Santini,
- Anja Bošnjaković,
- Mario Lovrić and
- Martina Lovrić Benčić
Background: Diabetes is the primary contributor to cardiovascular disease risk, and when combined with obesity, it further underscores the significance of cardiovascular risk assessment. Methods: A retrospective study of 64 patients with type 2 diabe...